In this systematic review and meta-analysis, we analyzed VTE incidence as well as the estimated risk for VTE in lung cancer patients with driver genes including ROS1, ALK, EGFR and KRAS. Patients with ROS1 and ALK rearrangements showed the highest incidence for VTE, and the risk of VTE in ALK rearranged patients was double of that observed in ALK wild type patients. This evidence concerns the gene EGFR and lung carcinoma.